



Year: 2017

Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up

Siegenthaler, M ; Huynh-Do, Uyen ; Krayenbuehl, P ; Pollock, E ; Widmer, U ; Debaix, H ; Olinger, E ; Frank, M ; Namdar, M ; Ruschitzka, F ; Nowak, Albina

Abstract: Aims: Fabry disease (FD) is a rare X-linked lysosomal storage disease with a deficiency of α -galactosidase A leading to progressive sphingolipid accumulation in different organs, among them heart and kidney. We evaluated the impact of cardio-renal syndrome (CRS) on the incidence of major cardiovascular complications and death in a prospective FD cohort. Methods and results: A total of 104 genetically proven FD patients were annually followed at the University Hospitals Zurich and Bern. The main outcome was a composite of incident renal replacement therapy (RRT), hospitalisation due to decompensated Heart Failure, new onset atrial fibrillation, pacemaker/ICD implantation, stroke/TIA and death. Estimated glomerular filtration rate (eGFR) and left ventricular myocardial mass index (LVMMI) were explored as the primary exposure variables. During the median follow-up of 103 [59–155] months, events occurred in 27 patients. In a Cox regression analysis, both higher LVMMI and lower eGFR were independently associated with a greater risk of developing adverse events after adjustment for multiple confounders (HR 1.67 [1.04–2.73] $P = 0.03$ per SD increase in LVMMI, HR 0.45 [0.25–0.83], $P = 0.01$ per SD decrease in eGFR). In patients with CRS, the risk to develop events was significantly increased if adjusted for demographics and RRT (HR 4.46 [1.07–18.62], $P = 0.04$), approaching significance if additionally adjusted for hypertension (HR 4.05 [0.95–17.29], $P = 0.06$). In Kaplan-Meier-Analysis, the poorest event-free survival was observed among patients with CRS. Conclusions: CRS was associated with a high risk to develop cardiovascular complications and death, emphasizing the importance of its prevention and early recognition. A focus on cardio-reno-protective therapies is crucial.

DOI: <https://doi.org/10.1016/j.ijcard.2017.09.027>

Posted at the Zurich Open Repository and Archive, University of Zurich

ZORA URL: <https://doi.org/10.5167/uzh-140662>

Journal Article

Accepted Version



The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:

Siegenthaler, M; Huynh-Do, Uyen; Krayenbuehl, P; Pollock, E; Widmer, U; Debaix, H; Olinger, E; Frank, M; Namdar, M; Ruschitzka, F; Nowak, Albina (2017). Impact of cardio-renal syndrome on adverse

outcomes in patients with Fabry disease in a long-term follow-up. *International Journal of Cardiology*, 249:261-267.
DOI: <https://doi.org/10.1016/j.ijcard.2017.09.027>

Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up

M. Siegenthaler ^{1,2}, U. Huynh-Do ³, P. Krayenbuehl ², E. Pollock ⁴, U. Widmer ¹, H. Debaix ⁵, E. Olinger ⁵, M. Frank ⁶, M. Namdar ⁷, F. Ruschitzka ⁶, A. Nowak ¹

¹ Department of Internal Medicine, University Hospital of Zurich, Switzerland; ² Department of Internal Medicine, Linth Hospital, Uznach, Switzerland; ³ Department of Nephrology, Hypertension and Clinical Pharmacology, University Hospital Bern, Switzerland; ⁴ Department of Nephrology, University Hospital of Zurich, Switzerland; ⁵ Institute of Physiology, University of Zurich, Switzerland; ⁶ Department of Cardiology, University Heart Centre, University Hospital Zurich, Switzerland; ⁷ Department of Cardiology, Geneva University Hospital, Switzerland

Correspondence:

Dr. Albina Nowak
Department of Internal Medicine
University Hospital Zurich
Rämistrasse 100
CH-8091 Zürich
Phone: 0041-44-255 10 54, Fax: 0041-44-255 45 67
Email: albina.nowak@usz.ch

Potential conflicts of interest:

A. Nowak received speaker honoraria, research support from Shire and Genzyme and publication support of this article from Genzyme. M. Namdar reports grants and personal fees from Genzyme, outside the submitted work.

Abstract

Aims. Fabry disease (FD) is a rare X-linked lysosomal storage disease with a deficiency of α -galactosidase A leading to progressive sphingolipid accumulation in different organs, among them heart and kidney. We evaluated the impact of cardio-renal syndrome (CRS) on the incidence of major cardiovascular complications and death in a prospective FD cohort.

Methods and results. A total of 104 genetically proven FD patients were annually followed at the University Hospitals Zurich and Bern. The main outcome was a composite of incident renal replacement therapy (RRT), hospitalisation due to decompensated Heart Failure, new onset atrial fibrillation, pacemaker/ICD implantation, stroke/TIA and death. Estimated glomerular filtration rate (eGFR) and left ventricular myocardial mass index (LVMMI) were explored as the primary exposure variables. During the median follow-up of 103 [59-155] months, events occurred in 27 patients. In a Cox regression analysis, both higher LVMMI and lower eGFR were independently associated with a greater risk of developing adverse events after adjustment for multiple confounders (HR 1.67 [1.04-2.73], $P=0.03$ per SD increase in LVMMI, HR 0.45 [0.25-0.83], $P=0.01$ -per SD decrease in eGFR). In patients with CRS, the risk to develop events was significantly increased if adjusted for demographics and RRT (HR 4.46 [1.07-18.62], $P=0.04$), approaching significance if additionally adjusted for hypertension (HR 4.05 [0.95-17.29], $P=0.06$). In Kaplan-Meier-Analysis, the poorest event-free survival was observed among patients with CRS.

Conclusions. CRS was associated with a high risk to develop cardiovascular complications and death, emphasizing the importance of its prevention and early recognition. A focus on cardio-reno-protective therapies is crucial.

Keywords. Fabry disease, cardio-renal syndrome, risk factors

Introduction

Fabry disease (FD) is an X-linked lysosomal storage disorder in which mutations of the *GLA* gene cause a decreased or absent activity of the enzyme alpha-galactosidase A (α -Gal A) and subsequent progressive intracellular accumulation of globotriaosylceramide (Gb₃) and other sphingolipids in various tissues^{1,2}. The initial classic signs and symptoms include acroparaesthesias, angiokeratoma, abdominal pain, hypohidrosis, corneal dystrophy and typically appear in childhood. With advancing age, vital organ dysfunction increasingly occurs resulting in cardiovascular disease, renal failure and premature strokes, on average more severely in males³. Combined renal and cardiac dysfunction is common in FD and associated with an increased mortality and morbidity risk^{4,5}.

Cardio-renal syndrome (CRS) is an increasingly recognized clinical entity which refers to the reciprocal association between cardiac and renal dysfunction, whereby injury to one organ directly promotes deterioration of the other⁶. This complex bilateral organ crosstalk can result from a variety of conditions where the primary failing organ may be the heart, the kidney or both. The latter is defined as CRS Type 5 and occurs secondarily to an underlying systemic process. FD is a typical example of the CRS Type 5, as described very recently⁷. CRS has been related to a particularly high morbidity and mortality in several settings^{6,8,9}, however, little is known about its impact on adverse long-term outcomes in FD patients.

In patients with FD, the indexed left ventricular myocardial mass (LVMMI) has repeatedly been shown to be a reliable parameter reflecting the onset and progression of Fabry disease-related cardiomyopathy^{10,11}. The estimated glomerular filtration rate (eGFR) has been used to quantify the renal involvement and shown to be a major risk factor for cardiovascular complications in FD⁵. The aim of this study was to assess the impact of CRS, reflected by LVMMI and eGFR, on clinical outcomes in a large prospective multicentre cohort of genetically confirmed FD patients and a long-term follow-up. The recognition of CRS should

79 lead to specific prevention strategies and therapeutic approaches in order to at least attenuate
80 the organ failure in those patients.

Methods

This is a retrospective analysis of a prospective, multi-centre cohort in Switzerland. The study was conducted in accordance with the principles of the Helsinki Declaration. The patients who could be contacted gave written informed consent. The authors have read and approved the manuscript.

Study population and treatment

The prospective FD cohort consisted of 104 patients, who were genetically tested (for further information see the Supplementary Table online). The cohort was established in 2001 when enzyme replacement therapy (ERT) was newly developed and offered to all FD patients. Consecutive FD patients were registered and received routine annual multidisciplinary examinations at two tertiary care hospitals – University Hospitals Zürich (93 patients) and Bern (11 patients). Here, we report on the clinical course and adverse outcomes of 64 females and 40 males.

The baseline clinical evaluation was performed at the time the patients were included in the cohort. For the present analysis, the clinical data and information on hospitalisation were extracted from medical records.

FD patients in Switzerland are personally followed-up and examined at the Fabry Centres, the adverse events were evaluated during annual examinations. All patients had a comprehensive workup, including medical history, cardiac evaluation with echocardiography, renal, and neurological evaluations. A 24- or 48 hours ECG was performed annually and additionally if patients complained of palpitations or chest pain. Hospitalisation was defined as a hospital stay for at least 24 hours. Standard transthoracic 2D-echocardiography was routinely performed in all patients.

For the evaluation of diastolic dysfunction, the left atrial volume index (LAVI), the mitral inflow (E/A ratio) and the mitral annular movement with tissue Doppler (e' septal and

lateral as well as an average of E/e' ratio) was measured according to the current practice guidelines^{12,13}. These measurements were performed using continuous recordings of mitral inflow, analysing the pulsed-wave during 10 seconds: the peak E-wave velocity (cm/sec) in early diastole, the A-wave (cm/sec) in late diastole at the leading edge of the spectral waveform and the pulsed wave tissue Doppler e' velocity (cm/sec) in early diastole. These measurements were available in the Zurich subgroup (N=82) of patients. Diastolic dysfunction has been graded according to the recent algorithm from the ASE/EACVI recommendations for the evaluation of the left ventricular diastolic function¹³ by reviewing and repeating all measurements of the archived echocardiographic studies.

Enzyme replacement therapy was initiated according to the written local guidelines and prescribed at the licensed dose of either 0.2 mg/kg body weight of recombinant α -agalsidase (Replagal) or 1 mg/kg body weight β -agalsidase (Fabrazyme) and given intravenously every 14 days. According to the guidelines, ERT was indicated in all males. In females, ERT was indicated if they had proteinuria of more than 300 mg per day, Fabry-typical kidney biopsy findings, signs of Fabry cardiomyopathy such as left ventricular hypertrophy or arrhythmia, stroke or transient ischemic attack (TIA), acroparesthesias despite conventional analgesic therapy, and/or gastrointestinal symptoms.

Endpoint definition and evaluation

As a primary endpoint, we defined the composite of requiring renal replacement therapy (RRT) (kidney transplantation or chronic dialysis), newly diagnosed atrial fibrillation (AF) of any type (paroxysmal/persistent), pacemaker and/or ICD implantation, hospitalisation due to decompensated heart failure (HF), cerebrovascular events (stroke or TIA), and death, whichever occurred first. The follow-up was censored at the date of the first event to calculate hazard ratios. The follow-up time for patients without events was censored at the 1st of July 2015. If the patients died outside of the Fabry Centre, the date of death was evaluated by

asking the responsible General Practitioner, the family or the nurse administering ERT in the home care setting.

Primary exposure variables: cardiac and renal involvement

LVMMI at baseline was used as the primary exposure variable to express cardiac involvement. For this, standard transthoracic 2D echocardiography was routinely performed in all patients. Left ventricular end-diastolic dimension and end-diastolic thickness of the posterior wall and the septum were measured using standard M-mode echocardiographic methods in parasternal long-axis images. LVMMI was calculated using the Devereux formula¹⁴.

Estimated glomerular filtration rate (eGFR) at baseline was used as the primary exposure variable to express renal involvement. The eGFR was derived from serum creatinine and age using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)¹⁵. The CKD-EPI equation is known to have a similarly good statistical performance as previously used equations when the estimated GFR is below 60 ml/min/1.73m², but with better performance in those with higher eGFR levels¹⁶.

Statistical analysis

We used descriptive statistics for the baseline characteristics and laboratory parameters. Categorical variables were expressed as proportions, continuous variables as means with standard deviations and medians with interquartile ranges (IQR). Normal distribution was assessed by the Kolmogorov-Smirnov-Test.

The cut-off values for LVMMI and eGFR were calculated by maximizing the product of sensitivity and specificity by using receiver operating curve characteristics (ROCs). Kaplan-Meier analysis was performed for event-free survival and log-rank values to assess statistical significance.

Cox regression analysis was used to examine the risk of adverse events associated with baseline LVMMI and eGFR on a continuous scale and for cardiac, renal and cardio-renal involvement as categorical variables. For the categorization, cardiac involvement was defined as LVMMI above the best calculated cut-off value of 107 (g/m²), we used this value for both genders because males have a higher LVMMI and a higher risk to develop adverse outcomes due to the hemizyosity; renal involvement was defined as eGFR below the best calculated cut-off value of 90 ml/min/1.73m²; CRS was defined as LVMMI > 107 (g/m²) and eGFR < 90 ml/min/1.73m².

Multivariable models were applied to adjust for potential confounders using prior knowledge of variables that have been associated with risk in FD patients in previous studies. We hierarchically adjusted for demographics (age, gender) in model 1, RRT (kidney transplant or dialysis at baseline) in model 2 and presence of arterial hypertension (systolic RR > 140 or diastolic RR > 90 mmHg or intake of antihypertensive drugs) in model 3. These models were used for all multivariable Cox regression analyses.

To evaluate the effect of ERT on the primary endpoint, Cox regression analysis was used, where ERT was expressed as a categorical covariate. In a multivariate Cox regression analysis, an adjustment for age and gender and for cardio-renal involvement was applied to evaluate if the ERT effect remained independent.

The statistical analyses were performed using the SPSS/PC (version 22.0; SPSS Inc., Chicago, IL, USA) software package. All statistical tests were two-sided, and P values <0.05 were considered significant.

Results

The baseline characteristics of all patients according to gender and to the presence of CRS are shown in Table 1. In total, 104 patients (40 males and 64 females) with a mean age of 45 ± 16 years were included into the analysis. A baseline echocardiography was available in 91, results on diastolic dysfunction in 82 patients. The left ventricular ejection fraction (LVEF) was normal in all patients. The patients with cardio-renal involvement at baseline were older, had more frequently a Classic disease phenotype, arterial hypertension, echocardiographic signs of diastolic dysfunction, had higher serum NT-proBNP levels and elevated urine protein/creatinine ratios.

Angiotensin converting enzyme inhibitor (ACE-i) or angiotensin receptor blocker (ARB) were used in 17 (16%) of the 104 patients at baseline. During the follow-up time, ACE-i or ARB were started in a further 17 patients.

The NYHA classes at baseline are summarized in Table 1. At the end of the follow-up time, NYHA I/II was present in 23 (22%) patients: 7 (18%) males, 16 (25%) females and 10 (23%) in patients with CRS at baseline; NYHA III/IV was present in 9 (8.6%) patients: 5 (13%) males, 4 (6.3%) females and 5 (12%) patients with CRS at baseline. NYHA class increased in 24 (23%) patients: 11 (28%) males, 13 (20%) females and 9 (21%) CRS patients.

48 patients were treated with α -agalsidase and nine with β -agalsidase throughout the follow-up time. Eight patients were switched from β -agalsidase to α -agalsidase (seven due to shortage of β -agalsidase, one at the discretion of the treating physician), one from α -agalsidase to β -agalsidase (due to patient's priority) and one from β -agalsidase to α -agalsidase (due to shortage) and back to β -agalsidase (due to patient's priority).

Events

During the median follow-up time of 105 [45-139] months, the first event occurred in 27 (26%) of the patient population: in 11 patients, the first event was stroke or TIA, in 2 kidney

transplantation, in 4 chronic dialysis, in 2 hospitalisation due to decompensated HF, in 8 death. 15 (56%) of the 27 patients who developed an event during the follow-up time had cardio-renal involvement at baseline. A pacemaker implantation or AF did not occur as a first event.

Overall, 57 events occurred: 4 patients had a new kidney transplantation, of whom 3 (75%) had cardio-renal involvement at baseline; 4 began chronic dialysis, of whom 3 (75%) had cardio-renal involvement at baseline; 2 patients were hospitalised due to decompensated HF, both (100%) with cardio-renal involvement at baseline; 11 had at least one stroke or TIA, 8 (73%) of whom had cardio-renal involvement at baseline; 7 had new-onset AF, of whom 6 (86%) had cardio-renal involvement at baseline; 6 underwent pacemaker and/or ICD implantation (with one appropriate shock secondary to sustained ventricular tachycardia in one patient during the entire follow-up period), all of whom had cardio-renal involvement at baseline. Of these 6 patients, 3 received a pacemaker due to symptomatic second- or third-degree atrioventricular block and one due to sinus dysfunction; 3 had an ICD implanted due to recurrent sustained and hemodynamically not tolerated ventricular tachycardia. 11 patients died: 2 due to cardiac arrhythmia, 2 malignancy, 1 infection, 1 suicide, 5 unknown; 6 (55%) of the deceased had cardio-renal involvement at baseline. The two male patients (59 and 47 years old) who died from cardiac arrhythmia, (one ventricular tachycardia and one asystole with pulseless electrical activity) suffered from cardiomyopathy, had kidney transplantation and a moderate infection.

The prognostic accuracy of baseline LVMMI and eGFR to predict major adverse clinical events using ROC curves was moderate to high as shown in the supplementary material (figure 1). We calculated an area under the curve of 0.81 for LVMMI and 0.86 for GFR. The best calculated cut-off for the events development was 107 g/m² for LVMMI and 90 ml/min/1.73m² for eGFR.

When examining continuous variables using Cox regression analysis, both higher LVMMI (Table 2A) and lower eGFR (Table 2B) at baseline were associated with a greater risk of developing an adverse clinical event in the crude model, after adjustment for possible confounders in model 1, model 2 and in the fully adjusted model 3. Of note, LVMMI and eGFR were associated with adverse events independently from each other if included into the same fully adjusted model (Table 2B).

Protein/creatinine ratio in a random urine sample and cholesterol levels were not associated with the adverse events in the crude model. These data are not shown. Smoking was associated with adverse events in the crude Cox regression analysis (HR 2.28 [1.03-5.03], $P=0.04$) but lost its independent effect on event occurrence after adjustment for male gender (HR 2.05 [0.91-4.63], $P=0.09$).

When examining categorical variables in a Cox regression analysis where (i) cardiac involvement is defined as LVMMI above the best calculated cut-off ($>107 \text{ g/m}^2$), (ii) renal involvement as eGFR below the best calculated cut-off ($<90 \text{ ml/min/1.73m}^2$) and (iii) CRS as both simultaneously, the risk to develop events was higher in patients with CRS as compared to all patients with cardiac and to all patients with renal involvement (Table 3) in a crude model. The Cox regression model for CRS remained significant after adjusting for possible confounders in model 1 and model 2, and approached significance in the fully adjusted model.

The cumulative dose of ERT did not influence the occurrence of clinical events for α -agalsidase, β -agalsidase and the sum of both in patients with cardiac (HR 0.88 [0.68-1.15], $P=0.36$ for α -agalsidase; HR 1.04 [0.97-1.11], $P=0.24$ for β -agalsidase; HR 1.04 [0.96-1.12], $P=0.36$ for sum), renal (HR 0.89 [0.73-1.08], $P=0.24$ for α -agalsidase; HR 1.06 [1.00-1.13], $P=0.07$ for β -agalsidase, HR 1.04 [0.97-1.12], $P=0.23$ for sum) and cardio-renal (HR 0.85 [0.64-1.12], $P=0.24$ for α -agalsidase; HR 1.05 [0.98-1.12], $P=0.20$ for β -agalsidase; HR 1.04 [0.87-1.12], $P=0.35$ for sum) involvement (all per 1 g increase and in fully adjusted model).

If defining only RRT, hospitalisation due to decompensated HF, cerebrovascular events (stroke or TIA), and death as the endpoint for the Cox regression model, excluding AF as an event of a less clinical severity, higher LVMMI and lower eGFR at baseline remained associated with a greater risk of developing an adverse clinical event in the crude model (HR 2.21 [1.43-3.42], $P < 0.001$ for LVMMI, HR 0.41 [0.27-0.62], $P < 0.001$ for eGFR), and remained significant for the eGFR approaching the significance for LVMMI after adjustment for possible confounders in model 1, (HR 1.65 [0.91-2.97], $P = 0.10$ for LVMMI, HR 0.41 [0.24-0.71], $P = 0.001$ for eGFR) model 2, (HR 1.74 [0.94-3.20], $P = 0.08$ for LVMMI, HR 0.37 [0.20-0.70], $P = 0.002$ for eGFR) and in the fully adjusted model 3 (HR 1.76 [0.98-3.18], $P = 0.06$ for LVMMI, HR 0.39 [0.20-0.76], $P = 0.006$ for eGFR) (all models per SD increase in LVMMI and SD decrease in eGFR).

When examining the effects of ERT on event occurrence, patients on ERT were at higher risk in the crude model (HR 11.62 [1.57-86.05], $P = 0.02$) and after adjustment for age and gender (HR 9.37 [1.21-72.47], $P = 0.03$). However, this “negative” ERT effect was attenuated after adjustment for cardio-renal involvement at baseline (HR 6.09 [0.76-49.06], $P = 0.09$).

In the Kaplan-Meier-Analysis, the poorest event-free survival was observed among patients with baseline cardio-renal involvement (Figure 1, A-C). This effect outweighed the gender-related difference in outcome within the cohort (Figure 1, D).

The associations remained unchanged if patients with the mutations c.376A>G / p.S126G and c.416A>G / p.N139S were excluded from the analysis, due to genetic variants of unknown significance.

Diastolic dysfunction

At baseline, 22 of 82 (27%) patients had a diastolic dysfunction. Of them, six (27%) showed an abnormal relaxation pattern - corresponding to diastolic dysfunction grade 1; twelve (55%)

pseudonormal filling dynamics - grade 2; three (14%) restrictive filling dynamics – grade 3; one (4.5%) was inconclusive.

When analysing the parameters of diastolic dysfunction on a continuous scale, E/e⁰ was a significant predictor for the occurrence of adverse clinical events in a crude (HR 1.90 [1.44-2.50], P<0.001) model and remained an independent predictor in model 1 (HR 1.63 [1.3-2.35], P=0.01), model 2 (HR 1.68 [1.15-2.46], P=0.007) and model 3 (HR 1.85 [1.23-2.78], P=0.003] (per SD increase). In contrast, LAVI predicted event occurrence in the crude (HR 1.85 [1.33-2.57], P<0.001) but not in the adjusted models (HR 1.23 [0.80-1.88], P=0.35 for model 1, HR 1.31 [0.81-2.12], P=0.27 model 2 and HR 1.49 [0.89-2.52], P=0.13 model 3, (all per SD increase).

Hospitalisations

All-cause hospitalisations. Overall, 28 of 104 patients were hospitalised during the follow-up period: 15 of 29 (52%) patients with and 13 (17%) of 75 without cardio-renal syndrome at baseline were ever hospitalised.

From a total of 79 hospitalisations (15 due to cardiac event or cardiac-related procedure; 8 TIA or stroke, 10 related to RRT, 4 due to pain, 23 infection, 2 malignancy, 17 other), 57 (72%) occurred in patients with and 22 (28%) without cardio-renal syndrome at baseline.

Cardiac hospitalisations

Overall, 9 of 104 patients were hospitalised due to a cardiac event or procedure. All of these patients had cardio-renal syndrome at baseline. In total, 15 cardiac hospitalisations occurred: 8 due to pacemaker/ICD implantation and related complications, 2 acute coronary events, 2 aortic valve replacements, 2 decompensated heart failure, 1 arrhythmic event.

Discussion

In this prospective multicentre cohort of 104 Swiss Fabry patients, CRS was associated with a high risk of complications such as death, stroke/TIA, hospitalisation due to decompensated HF and requirement for renal replacement therapy. Cardiac and renal disease independently increased the risk for major clinical events. Interestingly, cardio-renal involvement was a more important independent risk factor than male gender, despite the fact that FD is an X-linked inherited disorder.

Concurrent cardiac and renal involvement may reflect an advanced Gb3 deposition in the vital organs. Indeed, studies have demonstrated that patients with advanced stages of FD tend to experience disease progression and benefit less from enzyme replacement therapy^{17,18}. Moreover, cardio-renal involvement was often associated with the more severe classic FD phenotype; in contrast, single-organ manifestations seemed to correspond to the later-onset phenotype, which is known for a milder vascular risk profile¹⁹. Furthermore, renal disease itself has been shown to be a major risk factor for cardiovascular complications in FD⁵. Similarly, left ventricular hypertrophy was a significant predictor for cardiovascular events in a large-scale registry-based long-term study²⁰.

Additional pathophysiological mechanisms beyond glycosphingolipid deposition have been proposed to enhance the cardio-renal problem in patients with Fabry disease. On the cellular level, the lysosomal dysfunction may trigger a damaging cascade of events such as cell apoptosis, energy depletion²¹, increased oxidative stress²², inflammation²³ and finally cardiac^{24,25} and renal tissue fibrosis^{26,27}. On the organ level, left ventricular hypertrophy, diastolic dysfunction and arrhythmia can lead to a reduced cardiac output and a consecutive arterial underfilling resulting in reduced renal perfusion as well as renal venous congestion. On the other hand, reduced glomerular filtration rate causes salt and water retention, azotemia and acid base imbalance, further increasing the cardiac preload and predisposing to left ventricular and diastolic dysfunction. These haemodynamic derangements likely result in an

activation of the renin-angiotensin-aldosterone-system and a release of vasoactive mediators responsible for systemic vasoconstriction. Along the same lines, arterial hypertension has repeatedly been shown as an important risk factor in Fabry disease progression²⁰.

As shown in this study, diastolic dysfunction plays an important prognostic role in FD. Diastolic dysfunction is known to be an early sign of cardiac involvement in FD occurring before LVH²⁸. Our results are in line with a study by Boyd et al, in which left atrial enlargement and reduced atrial compliance in particular were shown as crucial early signs of Fabry cardiomyopathy²⁸. This left atrial enlargement as a result of chronic left atrial pressure elevation may lead to renal venous congestion, initiating the vicious cycle of CRS.

Cardiac and renal deterioration should consequently be prevented as far as possible in order to reduce morbidity and mortality. Within our cohort, patients on ERT were still at an increased risk of developing adverse clinical events, which continued to occur independently of the cumulative ERT dose, even after adjustment for possible confounders. The most likely reason for this observation is that ERT was indicated in patients with more severe phenotypes and was initiated relatively late. Importantly, we studied an “old” FD population where a large proportion of the patients had advanced disease, ERT having been initiated and offered to all FD patients from 2001. In this cohort, a high proportion of females (48%) was on ERT but could have been at lower risk of having major clinical events due to the heterozygosity. Therefore, in order to avoid bias by gender, adjustment for gender as a possible confounder has been introduced already in Model 1 and maintained in all multivariate models.

Of note in this study, we adopted a definition of CRS leading to a focus on patients with relatively “advanced” disease. Importantly, we studied an “older” adult FD population where a large proportion of the patients had advanced disease at baseline, because the cohort was established when ERT was initiated and offered to all FD patients in 2001. In the future, it is important to study the association of early disease involvement with clinical events because early ERT initiation benefits the clinical long-term outcome^{17,29}.

Because Gb3 accumulation is known to occur at early stages of Fabry nephropathy^{30,31} and cardiomyopathy³², early initiation of enzyme replacement therapy prior to overt kidney and heart disease may lead to prevention of CRS. Studies suggest that maximal treatment effect can be achieved at early stages of heart and kidney involvement^{33,34}.

To slow disease progression, more intensive therapies such as increased ERT dose or additional pharmacological chaperone therapy could enhance the therapeutic outcomes³⁵⁻³⁷. Fabry patients with advanced cardio-renal disease might additionally benefit from general therapies used to control cardiac and renal disease by RAAS inhibition using angiotensin-converting enzyme inhibitors or angiotensin blockers in the chronic and diuretic therapy in the acute setting. Patients with advanced disease should undergo a routine organ staging at regular intervals³⁸ and be treated according to current guidelines³⁹.

We included five patients with mutations c.376A>G / p.S126G and c.416A>G / p.N139S, reported in literature as genetic variants of unknown significance⁴⁰⁻⁴³. Three males, 55, 45 and 23 year old, and one female, 53 year old, with the mutation c.376A>G / p.S126G, had no cardiac or renal involvement at baseline and at 4 years follow-up, which confirms a rather benign nature of this mutation. Similarly, the 43 year old female with the mutation c.416A>G / p.N139S had no cardiac or renal involvement at baseline and at 2 years follow-up. Importantly, the associations with the clinical outcomes remained unchanged if patients with these mutations were excluded from the analysis.”

Several limitations merit consideration. Firstly, due to a relatively small cohort size, we had to define a composite outcome in order to increase the power of this study. Secondly, cardiac MRI was not available at cohort initiation. Thirdly, we cannot conclude from this study to what extent patients with cardio-renal involvement benefited from enzyme replacement therapy.

The strengths of this study are its long observational period for hard clinical outcomes in a multicentre cohort in a single country, where patients are treated similarly and exposed to

386 similar environmental conditions, and its negligible loss to follow-up. The latter is due to
387 Swiss regulation that the ERT prescription and patients` follow-up remains reserved for the
388 Fabry Centres.

389 In conclusion, cardio-renal involvement in Fabry disease is a potential marker of
390 disease progression bearing an increased risk of mortality and cardiovascular events.
391 Multidisciplinary care provided by cardiologists, nephrologists, general physicians and other
392 specialists is important in treating the Type 5 cardio-renal syndrome seen in Fabry disease.

393

References

1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. *Ann Intern Med*. 2003;138(4):338-346.
2. Rombach SM, Smid BE, Linthorst GE, Dijkgraaf MG, Hollak CE. Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages. *Journal of inherited metabolic disease*. 2014;37(3):341-352.
3. Schiffmann R, Warnock DG, Banikazemi M, et al. Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. *Nephrol Dial Transplant*. 2009;24(7):2102-2111.
4. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. *Eur J Clin Invest*. 2004;34(3):236-242.
5. Talbot AS, Lewis NT, Nicholls KM. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease. *Heart*. 2015;101(4):287-293.
6. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R. Cardiorenal syndrome. *J Am Coll Cardiol*. 2008;52(19):1527-1539.
7. Sharma A, Sartori M, Zaragoza JJ, et al. Fabry's disease: an example of cardiorenal syndrome type 5. *Heart Fail Rev*. 2015;20(6):689-708.
8. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. *Journal of cardiac failure*. 2007;13(8):599-608.
9. Pollock E, Nowak A. The cardiorenal problem. *Swiss Med Wkly*. 2014;144:w14051.
10. Weidemann F, Niemann M, Stork S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. *J Intern Med*. 2013;274(4):331-341.
11. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. *Int J Cardiol*. 2008;130(3):367-373.
12. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. *Eur J Echocardiogr*. 2009;10(2):165-193.
13. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2016;29(4):277-314.
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. *Circulation*. 1977;55(4):613-618.
15. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604-612.
16. Stevens LA, Schmid CH, Greene T, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m². *Am J Kidney Dis*. 2010;56(3):486-495.
17. Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. *J Med Genet*. 2015;52(5):353-358.
18. Schmied C, Nowak A, Gruner C, et al. The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy. *Heart*. 2016;102(16):1309-1314.
19. Rombach SM, van den Bogaard B, de Groot E, et al. Vascular aspects of Fabry disease in relation to clinical manifestations and elevations in plasma globotriaosylsphingosine. *Hypertension*. 2012;60(4):998-1005.
20. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. *J Am Coll Cardiol*. 2011;57(9):1093-1099.
21. Lucke T, Hoppner W, Schmidt E, Illsinger S, Das AM. Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts. *Molecular genetics and metabolism*. 2004;82(1):93-97.
22. Chimenti C, Scopelliti F, Vulpis E, et al. Increased oxidative stress contributes to cardiomyocyte dysfunction and death in patients with Fabry disease cardiomyopathy. *Human pathology*. 2015;46(11):1760-1768.
23. Biancini GB, Vanzin CS, Rodrigues DB, et al. Globotriaosylceramide is correlated with oxidative stress and inflammation in Fabry patients treated with enzyme replacement therapy. *Biochim Biophys Acta*. 2012;1822(2):226-232.
24. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. *Eur Heart J*. 2005;26(12):1221-1227.
25. Beer M, Weidemann F, Breunig F, et al. Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. *Am J Cardiol*. 2006;97(10):1515-1518.
26. Alroy J, Sabnis S, Kopp JB. Renal pathology in Fabry disease. *J Am Soc Nephrol*. 2002;13 Suppl 2:S134-138.
27. Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). *Nephrol Dial Transplant*. 2010;25(7):2168-2177.
28. Boyd AC, Lo Q, Devine K, et al. Left atrial enlargement and reduced atrial compliance occurs early in Fabry cardiomyopathy. *J Am Soc Echocardiogr*. 2013;26(12):1415-1423.

29. Ortiz A, Abiose A, Bichet DG, et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry. *J Med Genet.* 2016;53(7):495-502.
30. Tondel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. *Am J Kidney Dis.* 2008;51(5):767-776.
31. Tondel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients without albuminuria. *Nephron.* 2015;129(1):16-21.
32. Kampmann C, Wiethoff CM, Whybra C, Baehner FA, Mengel E, Beck M. Cardiac manifestations of Anderson-Fabry disease in children and adolescents. *Acta paediatrica.* 2008;97(4):463-469.
33. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. *Circulation.* 2009;119(4):524-529.
34. Tondel C, Bostad L, Larsen KK, et al. Agalsidase benefits renal histology in young patients with Fabry disease. *J Am Soc Nephrol.* 2013;24(1):137-148.
35. Germain DP, Giugliani R, Hughes DA, et al. Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies. *Orphanet journal of rare diseases.* 2012;7:91.
36. Ashe KM, Budman E, Bangari DS, et al. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease. *Mol Med.* 2015;21:389-399.
37. Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. *J Med Genet.* 2016.
38. Eng CM, Germain DP, Banikazemi M, et al. Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. *Genet Med.* 2006;8(9):539-548.
39. Biegstraaten M, Arngrimsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. *Orphanet journal of rare diseases.* 2015;10:36.
40. Colon C, Ortolano S, Melcon-Crespo C, et al. Newborn screening for Fabry disease in the north-west of Spain. *Eur J Pediatr.* 2017.
41. Pasqualim G, Simon L, Sperb-Ludwig F, et al. Fabry disease: a new approach for the screening of females in high-risk groups. *Clinical biochemistry.* 2014;47(7-8):657-662.
42. Oder D, Vergho D, Ertl G, Wanner C, Nordbeck P. Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles. *BMC Med Genet.* 2016;17(1):46.
43. Havndrup O, Christiansen M, Stoevring B, et al. Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women. *Eur J Heart Fail.* 2010;12(6):535-540.

Figures

Figure 1

Time to first complication in Fabry patients presented in groups using the best calculated cut-offs for LVMMI and eGFR at baseline (A), eGFR at baseline (B), LVMMI at baseline (C) and according to gender (D).




Table 1 Baseline characteristics, and laboratory parameters and cumulative ERT dose

	All patients	Males	Females	Patients with cardio-renal involvement ¹
	(n=104)	(n= 40)	(n=64)	(n=29; Males n=14)
Age (years)	45 ± 16	48 ± 14	44 ± 17	60 ± 10
Phenotype				
Classic n (%)	89 (86)	33 (83)	56 (88)	28 (97)
Later-Onset n (%)	15 (14)	7 (17)	8 (12)	1 (3)
BMI, (kg/m ²)	22 (20-25)	22 (19-23)	22 (20-26)	23 (22-25)
ERT n (%) ²	65 (63)	35 (88)	31 (48)	25 (86)
Cumulative dose α-agalsidase, g	3.0 (1.4-4.4) ³	3.4 (2.1-4.6)	2.2 (0.9-3.2)	3.4 (1.9-4.5)
Cumulative dose β-agalsidase, g	13.2 (5.1-19.3) ³	13.2 (6.5-21.8)	10.6 (4.2-16.9)	17.7 (10.2-20.6)
Mainz Severity Score Index	15 ± 11	21 ± 11	11 ± 8	25 ± 10
Systolic BP (mmHg)	120 (110-131)	124 (115-133)	120 (110-130)	129 (120-138)
Diastolic BP (mmHg)	80 (70-82)	80 (75-85)	78 (70-80)	80 (73-90)
Arterial hypertension n (%)	27 (26)	15 (38)	12 (19)	16 (55)
On ACE-i/ARB (%)	17 (16)	12 (30)	5 (8)	9 (31)
Diabetes mellitus n (%)	1 (1)	0	1 (2)	0
Cholesterol (mmol/l)	4.6 (4.1-5.6)	4.3 (3.9-5.4)	4.9 (4.2-5.7)	5.2 (4.3-6.1)
Smoker n (%)	37 (36)	21 (53)	16 (25)	12 (41)
NYHA I/II n (%)	13 (13)	5 (13)	8 (13)	9 (21)
NYHA III/IV n (%)	5 (4.8)	1 (2.5)	4 (6.3)	3 (7)
NT-proBNP, ng/l	435 ± 1222	683 ± 1938	305 ± 614	1083 ± 2131
Creatinine (μmol/l)	75 (67-91)	93 (82-132)	71 (64-76)	94 (75-131)
Protein/creatinine-ratio in urine (m g/mmol)	9 (6-24)	13 (7-39)	8 (4-17)	18 (9-42)
Chronic dialysis ⁴ n (%)	7 (7)	7 (18)	0	3 (10)
Renal transplantation n (%)	8 (8)	8 (20)	0	4 (14)
LVMMI (g/m ²)	89 (64-127)	109 (80-147)	75 (58-116)	147 (124-190)
LAVI (ml/m ²)	28 ± 11	30 ± 13	27 ± 10	39 ± 11
E/e (cm/sec)	8 ± 6	8 ± 3	8 ± 7	12 ± 8
Ejection Fraction, %	65 ± 7	65 ± 7	64 ± 6	66 ± 7
Atrial fibrillation n (%)	1 (1)	1 (2.5)	0 (0)	0 (0)
Pacemaker	1 (1)	0 (0)	1 (1.6)	0 (0)

Abbreviations: ACE-i = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure ERT = enzyme-replacement therapy; HR=Hazard Ratio;; LVMMI = left ventricular myocardial mass index, NYHA New York Heart Association functional class; TIA= transient ischemic attack.

Data are given as mean ± standard deviation, median (interquartile range) or numbers (%).

¹ patients with concurrent cardiac (LVMMI>107 g/m²) and renal (eGFR<90 ml/min/1.73m²) involvement at baseline

² four males were untreated due to mild phenotype, one due to compliance issue

³ only patients on ERT included in this analysis

⁴ at baseline or before kidney transplantation

Table 2 A. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline LVMMI.

Parameter	Crude			Model 1			Model 2			Model 3		
	HR	CI	P	HR	CI	P	HR	CI	P	HR	CI	P
LVMMI (g/m ²)**	2.14	1.52-3.01	<0.001	1.65	1.06-2.58	0.03	1.67	1.04-2.73	0.03	1.67	1.04-2.73	0.03
Age				1.03	1.00-1.07	0.045	1.03	1.00-1.07	0.06	1.02	0.98-1.06	0.26
Gender				1.56	0.63-3.87	0.34	1.68	0.66-4.32	0.28	1.55	0.60-3.97	0.37
Kidney transplant							0.47	0.07-3.18	0.44	0.42	0.07-2.66	0.36
Dialysis							2.36	0.41-13.68	0.34	2.05	0.11-3.21	0.40
Hypertension										1.92	0.71-5.21	0.20
eGFR										0.32	0.16-0.61	0.001

Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR= estimated glomerular filtration rate; HR=Hazard Ratio; CI=confidence interval

Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 3: additionally adjusted for presence of hypertension at baseline

* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cerebrovascular events (stroke or TIA), death

**per SD decrease

Table 2B. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline eGFR.

Parameter	Crude			Model 1			Model 2			Model 3		
	HR	CI	P	HR	CI	P	HR	CI	P	HR	CI	P
eGFR**	0.42	0.28-0.61	<0.001	0.45	0.27-0.74	0.002	0.42	0.24-0.74	0.003	0.45	0.25-0.83	0.01
Age				1.01	0.97-1.04	0.76	1.00	0.97-1.04	0.85	1.00	0.97-1.04	0.98
Gender				1.30	0.56-3.02	0.54	1.32	0.51-3.38	0.57	1.23	0.47-3.21	0.67
Kidney transplant							0.97	0.21-4.59	0.97	1.06	0.23-4.94	0.94
Dialysis							0.75	0.16-3.68	0.73	0.79	0.16-3.78	0.76
Hypertension										1.52	0.58-3.99	0.40

Abbreviations: LVMMI = left ventricular myocardial mass index; eGFR= estimated glomerular filtration rate; HR=Hazard Ratio; CI=confidence interval

Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 3: additionally adjusted for presence of hypertension at baseline

* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cerebrovascular events (stroke or TIA), death

** per SD decrease

Table 3. Hazard Ratios (and 95% CIs) for occurrence of primary endpoint* according to baseline cardiac, renal and cardio-renal involvement.

	Cardiac involvement ¹ (N=38)			Renal involvement ² (N=49)			Cardio-renal involvement ³ (N=29)		
	HR	95%CI	P	HR	95%CI	P	HR	95%CI	P
Crude	4.28	1.58-11.56	0.004	6.38	1.91-21.33	0.003	7.42	2.73-20.23	<0.001
Model 1	1.79	0.55-5.82	0.37	4.30	1.06-17.52	0.04	4.10	1.05-15.99	0.04
Model 2	1.83	0.56-5.97	0.32	4.88	1.12-21.24	0.04	4.46	1.07-18.62	0.04
Model 3	1.75	0.54-5.69	0.35	4.41	0.97-20.06	0.06	4.05	0.95-17.29	0.06

¹ all patients with cardiac (LVMMI>107 g/m²) involvement at baseline

² all patients with renal (eGFR<90 ml/min/1.73m²) involvement at baseline

³ patients with concurrent cardiac (LVMMI>107 g/m²) and renal (eGFR<90 ml/min/1.73m²) involvement at baseline

Model1: adjusted for age and male gender; Model 2: additionally adjusted for renal replacement - transplantation and dialysis at baseline; Model 3: additionally adjusted for presence of hypertension at baseline

* Primary endpoint was defined as a composite of first occurrence of renal replacement therapy requirement (kidney transplant or chronic dialysis), new onset of atrial fibrillation, pacemaker and/or ICD implantation, hospitalisation due to decompensated Heart Failure, cerebrovascular events (stroke or TIA), death

Supplementary Table 1. Genotype and phenotype of the included Fabry patients

Sex	Age	GLA Mutation / Predicted Enzyme Protein Change	Phenotype
male	33	c.125T>C / p.M42T	Classic
male	35	c.125T>C / p.M42T	Classic
male	23	c.125T>C / p.M42T	Classic
male	44	c.581C>T / p.T194I	Classic
male	67	c.581C>T / p.T194I	Classic
male	51	c.581C>T / p.T194I	Classic
male	36	c.581C>T / p.T194I	Classic
male	47	c.613C>T / p.P205S	Classic
male	44	c.744_745delTA / p.F248LfsX7	Classic
male	49	c.744_745delTA / p.F248LfsX7	Classic
male	39	c.827G>A / p.S276N	Classic
male	55	c.899T>A / p.L300H	Classic
male	59	c.899T>A / p.L300H	Classic
male	61	c.1033T>C / p.S345P	Classic
male	59	c.1033T>C / p.S345P	Classic
male	39	c.1033T>C / p.S345P	Classic
male	41	c.1033T>C / p.S345P	Classic
male	60	c.1033T>C / p.S345P	Classic
male	61	c.1033T>C / p.S345P	Classic
male	29	c.1055_1057dupCTA / p.A352_M353insT	Classic
male	27	c.1147_1149del / p.F383del	Classic
male	59	c.1167dupT / p.V390CfsX9	Classic
male	40	c.1167dupT / p.V390CfsX9	Classic
male	56	c.1167dupT / p.V390CfsX9	Classic
male	68	c.1167dupT / p.V390CfsX9	Classic
male	34	c.1167dupT / p.V390CfsX9	Classic
male	35	c.1167dupT / p.V390CfsX9	Classic
male	73	IVS6-10G>A / Cons. Splice Site	Classic
male	40	c.370-2A>G / Cons. Splice Site	Classic
male	44	c.370-2A>G / Cons. Splice Site	Classic
male	60	c.640-3C>G / Cons. Splice Site	Classic
male	50	Whole Exon 2 / Null-allele	Classic
male	75	Whole Exon 2 / Null-allele	Classic
female	63	c.72G>A / p.W24X	Classic
female	48	c.72G>A / p.W24X	Classic
female	26	c.125T>C / p.M42T	Classic
female	31	c.125T>C / p.M42T	Classic
female	29	c.125T>C / p.M42T	Classic
female	25	c.125T>C / p.M42T	Classic
female	36	c.154T>C / p.C52R	Classic
female	69	c.365delA / p.N122IfsX8	Classic
female	48	c.365delA / p.N122IfsX8	Classic
female	52	c.365delA / p.N122IfsX8	Classic
female	44	c.488G>T / p.G163V	Classic

female	34	c.581C>T / p.T194I	Classic
female	37	c.581C>T / p.T194I	Classic
female	68	c.581C>T / p.T194I	Classic
female	26	c.581C>T / p.T194I	Classic
female	22	c.581C>T / p.T194I	Classic
female	39	c.581C>T / p.T194I	Classic
female	65	c.581C>T / p.T194I	Classic
female	32	c.581C>T / p.T194I	Classic
female	32	c.581C>T / p.T194I	Classic
female	63	c.581C>T / p.T194I	Classic
female	29	c.704C>A / p.S235Y	Classic
female	62	c.744_745delTA / p.F248LfsX7	Classic
female	20	c.744_745delTA / p.F248LfsX7	Classic
female	39	c.744_745delTA / p.F248LfsX7	Classic
female	56	c.796G>T / p.D266Y	Classic
female	55	c.796G>T / p.D266Y	Classic
female	68	c.827G>A / p.S276N	Classic
female	48	c.870G>C / p.M290I	Classic
female	23	c.901C>T / p.R301X	Classic
female	35	c.901C>T / p.R301X	Classic
female	40	c.901C>T / p.R301X	Classic
female	42	c.1033T>C / p.S345P	Classic
female	16	c.1033T>C / p.S345P	Classic
female	68	c.1033T>C / p.S345P	Classic
female	25	c.1033T>C / p.S345P	Classic
female	28	c.1033T>C / p.S345P	Classic
female	51	c.1033T>C / p.S345P	Classic
female	29	c.1033T>C / p.S345P	Classic
female	23	c.1033T>C / p.S345P	Classic
female	65	c.1033T>C / p.S345P	Classic
female	72	c.1033T>C / p.S345P	Classic
female	31	c.1055_1057dupCTA / p.A352_M353insT	Classic
female	25	c.1147_1149del / p.F383del	Classic
female	57	c.1147_1149del / p.F383del	Classic
female	35	c.1167dupT / p.V390CfsX9	Classic
female	17	c.1167dupT / p.V390CfsX9	Classic
female	51	c.1167dupT / p.V390CfsX9	Classic
female	24	c.1167dupT / p.V390CfsX9	Classic
female	22	c.1167dupT / p.V390CfsX9	Classic
female	44	c.1167dupT / p.V390CfsX9	Classic
female	36	c.1235_1236delCT / p.T412SfsX38	Classic
female	41	c.640-3C>G / Cons. Splice Site	Classic
female	65	c.370-2A>G / Cons. Splice Site	Classic
female	83	Whole Exon 2 / Null-allele	Classic
female	68	Not available*	Classic
male	75	c.352C>T / p.R118C	Later-Onset
male	63	c.644A>G / p.N215S	Later-Onset

male	65	c.902G>A / p.R301Q	Later-Onset
male	44	c.902G>A / p.R301Q	Later-Onset
male	41	c.1196G>C / p.W399S	Later-Onset
female	33	c.337T>C / p.F113L	Later-Onset
female	37	c.902G>A / p.R301Q	Later-Onset
female	53	c.902G>A / p.R301Q	Later-Onset
female	73	c.902G>A / p.R301Q	Later-Onset
female	48	c.902G>A / p.R301Q	Later-Onset
male	45	c.376A>G / p.S126G	Benign
male	23	c.376A>G / p.S126G	Benign
male	55	c.376A>G / p.S126G	Benign
female	53	c.376A>G / p.S126G	Benign
female	41	c.416A>G / p.N139S	Benign
* The original genetic report of this patient, who died in between, was not any more available. The Classic phenotype has been confirmed by clinical symptoms: cardiomyopathy, nephropathy, cornea verticillata, hypohydrosis.			